Valuation: MedinCell S.A.

Market Cap 1.03B 1.14B 957M 864M 1.63B 108B 1.69B 11.5B 4.56B 57.52B 4.29B 4.2B 183B P/E 2027 *
812x
P/E 2028 * 54.4x
Enterprise Value 1.01B 1.11B 933M 842M 1.59B 105B 1.64B 11.21B 4.44B 56.07B 4.18B 4.09B 178B EV / Sales 2027 *
25.9x
EV / Sales 2028 * 17.4x
Free-Float
66.07%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: MedinCell S.A.

1 day-0.89%
1 week+1.34%
Current month+9.33%
1 month+9.50%
3 months+19.59%
6 months+5.26%
Current year+14.37%
1 week 28.4
Extreme 28.4
30.68
1 month 25.04
Extreme 25.04
30.68
Current year 19.69
Extreme 19.69
32.38
1 year 19.69
Extreme 19.69
32.38
3 years 5.92
Extreme 5.92
39.68
5 years 4.73
Extreme 4.73
39.68
10 years 4.35
Extreme 4.35
39.68
Manager TitleAgeSince
Chief Executive Officer 62 2003-01-08
Director of Finance/CFO 52 2023-08-31
Chief Operating Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 62 2003-01-08
Chairman - 2024-03-12
Director/Board Member - 2020-12-14
Date Insider Type Main position Quantity % Market Cap. Importance
10/21/26 Buy

Chief Executive Officer

70,000 0.1948%
2/26/25 Buy

General Counsel

2,943 0.0099%
2/21/25 Buy

Chief Financial Officer

3,749 0.0126%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+1.34%-5.32%+372.46% 1.14B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
-0.44%+3.69%+41.45%+70.04% 386B
+0.55%+0.70%+59.02%+45.79% 364B
-0.12%+0.74%+28.39%+60.32% 302B
+0.37%+0.37%+3.33%+38.57% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.15%+2.00%+31.32%+113.34% 430B
Weighted average by Cap. +0.54%+3.26%+37.69%+99.36%

Financials

2027 *2028 *
Net sales 38.94M 42.97M 36.02M 32.5M 61.24M 4.05B 63.4M 433M 172M 2.16B 161M 158M 6.87B 56.6M 62.46M 52.35M 47.24M 89.02M 5.89B 92.15M 629M 249M 3.15B 234M 229M 9.99B
Net income -2.73M -3.02M -2.53M -2.28M -4.3M -284M -4.45M -30.37M -12.04M -152M -11.32M -11.08M -482M 20.09M 22.17M 18.58M 16.77M 31.6M 2.09B 32.71M 223M 88.52M 1.12B 83.21M 81.44M 3.54B
Net Debt -26.23M -28.95M -24.26M -21.89M -41.26M -2.73B -42.71M -291M -116M -1.46B -109M -106M -4.63B -49.43M -54.55M -45.72M -41.25M -77.74M -5.14B -80.48M -549M -218M -2.75B -205M -200M -8.72B
Projected Income Statement - Annual - MedinCell S.A.
Logo MedinCell S.A.
MedinCell S.A. is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2026, the company had a portfolio of a product in phase III clinical development and 3 products in preclinical development.
Employees
141
Date Price Change Volume
26-11-13 €28.82 -0.89% 31,547
26-11-12 €29.08 -2.48% 63,297
26-11-11 €29.82 +0.20% 50,750
26-11-10 €29.76 -0.80% 117,587
26-11-09 €30.00 +5.49% 178,878
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - MedinCell S.A.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.82EUR
Average target price
36.18EUR
Spread / Average Target
+25.53%
  1. Stock Market
  2. Stocks
  3. MEDCL Stock